$REFR
RESEARCH FRONTIERS INC Stock $refr

$refr Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000149315224009207 Filed on March 07, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$313.4K	$312.2K	$909.6K
YoY Change	26.27%	140.37%	68.54%
Cost Of Revenue	$633.4K	$664.5K	$2.360M
YoY Change	7.76%	-15.38%	-7.67%
Gross Profit	-$320.0K	-$352.3K	-$1.450M
YoY Change	-5.77%	-46.25%	-28.07%
Gross Profit Margin	-102.12%	-112.82%	-159.41%
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development	$149.7K	$153.1K	$583.3K
YoY Change	0.35%	-7.04%	-4.25%
% of Gross Profit
Depreciation & Amortization	$6.450K	$7.350K	$27.35K
YoY Change	-5.43%	1.66%	-5.17%
% of Gross Profit
Operating Expenses	$783.1K	$153.1K	$2.943M
YoY Change	6.26%	-7.04%	-7.01%
Operating Profit	-$469.8K	-$505.4K	-$2.033M
YoY Change	-3.91%	-38.38%	-22.54%
Interest Expense	$27.15K	$25.48K	$124.9K
YoY Change	3.59%	447.96%	-382.54%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$442.6K	-$479.9K	-$1.908M
YoY Change	-4.33%	-41.15%	-28.51%
Income Tax
% Of Pretax Income
Net Earnings	-$442.6K	-$479.9K	-$1.908M
YoY Change	-4.33%	-41.15%	-28.51%
Net Earnings / Revenue	-141.24%	-153.7%	-209.8%
Basic Earnings Per Share	-$0.01		-$0.06
Diluted Earnings Per Share	-$0.01	-$0.01	-$0.06
COMMON SHARES
Basic Shares Outstanding	33.51M shares	33.51M shares	33.45M shares
Diluted Shares Outstanding	33.51M shares		33.45M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.093M	$2.476M	$2.476M
YoY Change	-49.44%	-41.48%	-41.48%
Cash & Equivalents	$2.100M	$2.500M	$2.476M
Short-Term Investments
Other Short-Term Assets	$240.8K	$96.78K	$96.78K
YoY Change	158.36%	-4.15%	-4.15%
Inventory
Prepaid Expenses
Receivables	$956.8K	$1.003M	$1.003M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$3.291M	$3.576M	$3.576M
YoY Change	-33.08%	-27.34%	-27.34%
LONG-TERM ASSETS
Property, Plant & Equipment	$33.20K	$39.60K	$218.3K
YoY Change	-43.99%	-39.44%	-43.86%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$56.07K	$56.07K	$56.07K
YoY Change	0.0%	0.0%	0.0%
Total Long-Term Assets	$232.2K	$274.4K	$274.4K
YoY Change	-42.21%	-38.34%	-38.34%
TOTAL ASSETS
Total Short-Term Assets	$3.291M	$3.576M	$3.576M
Total Long-Term Assets	$232.2K	$274.4K	$274.4K
Total Assets	$3.523M	$3.851M	$3.851M
YoY Change	-33.77%	-28.25%	-28.25%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$171.2K	$50.88K	$50.88K
YoY Change	573.11%	-28.42%	-28.42%
Accrued Expenses	$51.27K	$14.19K	$226.6K
YoY Change	9.72%	-58.72%	-1.83%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$439.5K	$277.4K	$277.4K
YoY Change	54.87%	-8.09%	-8.09%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$0.00	$55.36K	$55.36K
YoY Change	-100.0%	-79.32%	-79.32%
Total Long-Term Liabilities	$0.00	$55.36K	$55.36K
YoY Change	-100.0%	-79.32%	-79.32%
TOTAL LIABILITIES
Total Short-Term Liabilities	$439.5K	$277.4K	$277.4K
Total Long-Term Liabilities	$0.00	$55.36K	$55.36K
Total Liabilities	$439.5K	$332.8K	$332.8K
YoY Change	-12.23%	-41.57%	-41.57%
SHAREHOLDERS EQUITY
Retained Earnings	-$124.7M	-$124.3M
YoY Change	1.55%	1.55%
Common Stock	$127.8M	$127.8M
YoY Change	0.12%	0.49%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$3.100M	$3.500M	$3.518M
YoY Change
Total Liabilities & Shareholders Equity	$3.523M	$3.851M	$3.851M
YoY Change	-33.77%	-28.25%	-28.25%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$442.6K	-$479.9K	-$1.908M
YoY Change	-4.33%	-41.15%	-28.51%
Depreciation, Depletion And Amortization	$6.450K	$7.350K	$27.35K
YoY Change	-5.43%	1.66%	-5.17%
Cash From Operating Activities	-$391.1K	-$545.0K	-$2.295M
YoY Change	-34.5%	-3.9%	5.15%
INVESTING ACTIVITIES
Capital Expenditures	$50.00	$1.560K	$1.558K
YoY Change	-92.88%	3020.0%	22.58%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$2.497M	$57.15K
YoY Change	-100.0%		-97.88%
Cash From Investing Activities	-$50.00	$2.496M	$55.59K
YoY Change	-100.0%	-4991280.0%	-97.94%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$8.670K	4.500K	$484.5K
YoY Change	-98.21%		-85.96%
NET CHANGE
Cash From Operating Activities	-$391.1K	-545.0K	-$2.295M
Cash From Investing Activities	-$50.00	2.496M	$55.59K
Cash From Financing Activities	$8.670K	4.500K	$484.5K
Net Change In Cash	-$382.5K	1.955M	-$1.755M
YoY Change	-87.58%	-444.66%	-144.31%
FREE CASH FLOW
Cash From Operating Activities	-$391.1K	-$545.0K	-$2.295M
Capital Expenditures	$50.00	$1.560K	$1.558K
Free Cash Flow	-$391.2K	-$546.6K	-$2.297M
YoY Change	-34.57%	-3.64%	5.16%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Trading Symbol TradingSymbol	REFR
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0000793524
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities		usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2023	REFR	Proceeds From Sale Of Common Stock And Warrants ProceedsFromSaleOfCommonStockAndWarrants		usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther		usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures		shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
CY2023Q4	REFR	Lessee Operating Lease Liability Payments Due Year Four And Five LesseeOperatingLeaseLiabilityPaymentsDueYearFourAndFive		usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Entity File Number EntityFileNumber	000-14893
CY2023	dei	Entity Registrant Name EntityRegistrantName	RESEARCH FRONTIERS INCORPORATED
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	11-2103466
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	240 CROSSWAYS PARK DRIVE
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	WOODBURY
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	11797-2033
CY2023	dei	City Area Code CityAreaCode	(516)
CY2023	dei	Local Phone Number LocalPhoneNumber	364-1902
CY2023	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 Par Value
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	51773808	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	33509287	shares
CY2023	dei	Auditor Firm AuditorFirmId	596
CY2023	dei	Auditor Name AuditorName	CohnReznick LLP
CY2023	dei	Auditor Location AuditorLocation	Melville, New York
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2475958	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4230916	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1253450	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1158450	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1003404	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	589599	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	96784	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	100973	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	3576146	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	4921488	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	39598	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	65388	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	178715	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	323509	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	56066	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	56066	usd
CY2023Q4	us-gaap	Assets Assets	3850525	usd
CY2022Q4	us-gaap	Assets Assets	5366451	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	212359	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	196405	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	50880	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	71079	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14192	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	34379	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	277431	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	301863	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	55363	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	267723	usd
CY2023Q4	us-gaap	Liabilities Liabilities	332794	usd
CY2022Q4	us-gaap	Liabilities Liabilities	569586	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	33509287	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	33509287	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	33150396	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	33150396	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	3351	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	3315	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	127779221	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	127150027	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-124264841	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-122356477	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	3517731	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	4796865	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3850525	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5366451	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	909598	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	539686	usd
CY2023	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	2359634	usd
CY2022	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	2555689	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	583266	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	609127	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	2942900	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	3164816	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-2033302	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-2625130	usd
CY2023	us-gaap	Gain Loss On Investments GainLossOnInvestments	124938	usd
CY2022	us-gaap	Gain Loss On Investments GainLossOnInvestments	-44219	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-1908364	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2669349	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.06
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.08
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33453627	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33453627	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32070233	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	32070233	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	3783923	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	232291	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3450000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2669349	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	4796865	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	4796865	usd
CY2023	REFR	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	484502	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	144728	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-1908364	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	3517731	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	3517731	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-1908364	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2669349	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	27348	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	28837	usd
CY2023	us-gaap	Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments	57149	usd
CY2022	us-gaap	Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments	-60143	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	144728	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	232291	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	95000	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	141772	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	144794	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	146315	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	508805	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-100266	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-4189	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	30542	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-40386	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-10387	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-196406	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-182091	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2295051	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2182745	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1558	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1271	usd
CY2023	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	5434386	usd
CY2023	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	5491535	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	2694968	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	55591	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	2693697	usd
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	484502	usd
CY2022	REFR	Proceeds From Sale Of Common Stock And Warrants ProceedsFromSaleOfCommonStockAndWarrants	3450000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	484502	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3450000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1754958	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	3960952	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4230916	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	269964	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2475958	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4230916	usd
CY2023	us-gaap	Basis Of Accounting BasisOfAccounting	<p id="xdx_80D_eus-gaap--BasisOfAccounting_zAWouVBNplSb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1) <span style="text-decoration: underline"><span id="xdx_82E_zl51a8df1Wrf">Business and Basis for Presentation</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research Frontiers Incorporated (“Research Frontiers” or the “Company”) operates in a single business segment which is engaged in the development and marketing of technology and devices to control the flow of light. Such devices, often referred to as “light valves” or suspended particle devices (“SPDs”), use colloidal particles that are either incorporated within a liquid suspension or a film, which is usually enclosed between two sheets of glass or plastic having transparent, electrically conductive coatings on the facing surfaces thereof. At least one of the two sheets is transparent. SPD technology, made possible by a flexible light-control film invented by Research Frontiers, allows the user to instantly and precisely control the shading of glass/plastic manually or automatically. SPD technology has numerous product applications, including SPD-Smart™ windows, sunshades, skylights and interior partitions for homes and buildings; automotive windows, sunroofs, sun visors, sunshades, rear-view mirrors, instrument panels, heads up displays and navigation systems; aircraft windows; museum display panels; eyewear products; and flat panel displays for electronic products. SPD-Smart light control film is now being developed for, or used in, architectural, automotive, marine, aerospace and appliance applications.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has primarily utilized its cash, cash equivalents, and investments generated from sales of our common stock, proceeds from the exercise of options and warrants, and royalty fees collected to fund its research and development of SPD light valves, for marketing initiatives, and for other working capital purposes. The Company’s working capital and capital requirements depend upon numerous factors, including the results of research and development activities, competitive and technological developments, the timing and cost of patent filings, and the development of new licensees and changes in the Company’s relationships with its existing licensees. The degree of dependence of the Company’s working capital requirements on each of the foregoing factors cannot be quantified; increased research and development activities and related costs would increase such requirements; the addition of new licensees may provide additional working capital or working capital requirements, and changes in relationships with existing licensees would have a favorable or negative impact depending upon the nature of such changes. We have incurred recurring losses since inception and expect to continue to incur losses as a result of costs and expenses related to our research and continued development of our SPD technology and our corporate general and administrative expenses. Our limited capital resources and operations to date have been substantially funded through sales of our common stock, exercise of options and warrants and royalty fees collected. As of December 31, 2023, we had working capital of approximately $<span id="xdx_90C_ecustom--WorkingCapital_iI_pn5n6_c20231231_z2zgG9AEK6bd" title="Working capital">3.3</span> million, cash and cash equivalents of approximately $<span id="xdx_902_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20231231_zRx8Co9bZ8t2" title="Cash and cash equivalents">2.5</span> million, shareholders’ equity of approximately $<span id="xdx_901_eus-gaap--StockholdersEquity_iI_pn5n6_c20231231_zWar9IAQLvrj" title="Shareholders' equity">3.5</span> million and an accumulated deficit of approximately $<span id="xdx_901_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20231231_zUzTBJgeZebe" title="Accumulated deficit">124.3</span> million. Our quarterly projected cash flow shortfall, based on our current operations, adjusted for any non-recurring cash expenses and adjusted for additional royalties expected to be received for use of our products in new production, for the next 12 months, is approximately $<span id="xdx_904_ecustom--NonrecurringCashExpenses_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_z2hIAzYHpwpl" title="Non-recurring cash expenses">200,000</span> to $<span id="xdx_90A_ecustom--NonrecurringCashExpenses_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_z2so23nwyGL5" title="Non-recurring cash expenses">250,000</span> per quarter. We may eliminate some operating expenses in the future, which will further reduce our cash flow shortfall if needed. Based on these assumptions, we currently expect to have sufficient working capital for at least 12 months from the issuance of these financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the event that we are unable to generate sufficient cash from our operating activities or raise additional funds, we may be required to delay, reduce or severely curtail our operations or otherwise impede our on-going business efforts, which could have a material adverse effect on our business, operating results, financial condition and long-term prospects. The Company may seek to obtain additional funding through future equity issuances. There can be no assurance as to the availability or terms upon which such financing and capital might be available. The eventual success of the Company and generation of positive cash flow will be dependent upon the commercialization of products using the Company’s technology by the Company’s licensees and payments of continuing royalties on account thereof. To date, the Company has not generated sufficient revenue from its licensees to fund its operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q4	REFR	Working Capital WorkingCapital	3300000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2500000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	3500000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-124300000	usd
CY2023Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2023Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	1200000	usd
CY2023	REFR	Amortized Cost Term Description AmortizedCostTermDescription	These costs are required to be amortized over five years if the R&D activities are performed in the U.S., or over 15 years if the activities were performed outside the U.S.
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	583000	usd
CY2022Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	2700000	usd
CY2023	us-gaap	Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments	57149	usd
CY2022	us-gaap	Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments	-60143	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	609000	usd
CY2022Q3	REFR	Corporate Minimum Tax Rate CorporateMinimumTaxRate	0.15	pure
CY2023Q1	REFR	Excise Tax On Corporate Stock Rate ExciseTaxOnCorporateStockRate	0.01	pure
CY2023Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	110000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	109000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84E_eus-gaap--UseOfEstimates_zLldWXtUJ8Qk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) <span id="xdx_86F_zXaXb4vAG8l5">Use of Estimates</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the Company’s consolidated financial statements requires management of the Company to make a number of estimates and assumptions relating to the reported amount of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during this period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023	REFR	Recognized Benefit Measured RecognizedBenefitMeasured	greater than 50 percent
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2808308	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2806750	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2768710	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2741362	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	39598	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	65388	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	9032	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	29219	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	4800	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	4800	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	360	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	360	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14192	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	34379	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	263000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	248000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	12939000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	13561000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	257000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	334000	usd
CY2023Q4	REFR	Deferred Tax Assets Tax Credit Carryforwards Research And Other Credits DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOtherCredits	834000	usd
CY2022Q4	REFR	Deferred Tax Assets Tax Credit Carryforwards Research And Other Credits DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOtherCredits	891000	usd
CY2023Q4	REFR	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	56000	usd
CY2022Q4	REFR	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	99000	usd
CY2023Q4	REFR	Deferred Tax Assets Amortization DeferredTaxAssetsAmortization	225000	usd
CY2022Q4	REFR	Deferred Tax Assets Amortization DeferredTaxAssetsAmortization	130000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	35000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	14719000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	15372000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	38000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	69000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	38000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	69000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	14681000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	15303000	usd
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-401000	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-561000	usd
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	1023000	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	1011000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-622000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-450000	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	64587000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration	52995000	usd
CY2023	REFR	Operating Loss Carryforwards Expiration Description OperatingLossCarryforwardsExpirationDescription	expire in varying amounts from 2024 through 2038
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.80	pure
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	904000	usd
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	223000	shares
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	144728	usd
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	178000	shares
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	232291	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.02
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.31
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.75	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.81	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0384	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0399	pure
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	1399991	shares
CY2021Q4	REFR	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	2.27
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	1500000	shares
CY2022	REFR	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Issued In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePrice	2.76
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	2899991	shares
CY2022Q4	REFR	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	2.52
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	358891	shares
CY2023	REFR	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice	1.35
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures	461957	shares
CY2023	REFR	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Terminated In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsTerminatedInPeriodWeightedAverageExercisePrice	1.35
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	2079143	shares
CY2023Q4	REFR	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	3.20
CY2023	REFR	Lease Expiration Term LeaseExpirationTerm	P1Y
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y3M18D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.055	pure
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	222000	usd
CY2023Q4	REFR	Lessee Operating Lease Liability Payments Due Year Two And Three LesseeOperatingLeaseLiabilityPaymentsDueYearTwoAndThree	56000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	278000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	10278	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	267722	usd
CY2023	REFR	Percentage Of Acquisition Threshold In Rights Agreement PercentageOfAcquisitionThresholdInRightsAgreement	0.15	pure
CY2023Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	80
CY2023Q4	REFR	Discount Price Of Stock DiscountPriceOfStock	40
CY2023Q4	REFR	Acquiring Assets Percent AcquiringAssetsPercent	0.50	pure
CY2023Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	80
CY2023Q4	REFR	Discount Price Of Stock DiscountPriceOfStock	40
CY2023	REFR	Rights Plan Expire Date RightsPlanExpireDate	2033-02-11
CY2023Q4	REFR	Rights Redemption Price Per Share RightsRedemptionPricePerShare	0.0001

Files In Submission

Name	View Source	Status
0001493152-24-009207-index-headers.html	Edgar Link	pending
0001493152-24-009207-index.html	Edgar Link	pending
0001493152-24-009207.txt	Edgar Link	pending
0001493152-24-009207-xbrl.zip	Edgar Link	pending
ex21.htm	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
form10-k_htm.xml	Edgar Link	completed
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
refr-20231231.xsd	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
refr-20231231_cal.xml	Edgar Link	unprocessable
refr-20231231_def.xml	Edgar Link	unprocessable
refr-20231231_lab.xml	Edgar Link	unprocessable
refr-20231231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$REFR
RESEARCH FRONTIERS INC Stock $refr

2024 Q1 Form 10-K Financial Statement

#000149315224009207 Filed on March 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$REFR RESEARCH FRONTIERS INC Stock $refr

2024 Q1 Form 10-K Financial Statement

#000149315224009207 Filed on March 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$REFR
RESEARCH FRONTIERS INC Stock $refr